Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II non-randomized trial of ipilimumab monotherapy as first-line treatment in metastatic uveal melanoma
2010-024415-14Phase 2Completed
- Sponsor
- Institut Català d'Oncologia
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in uveal melanoma (UM) and melanoma, sponsored by Institut Català d'Oncologia. Primary endpoint: overall survival. Started Feb 2011; status: completed.
02
Drugs
ipilimumab
03
Conditions
uveal melanoma (UM)melanoma
Beyond the preview
Go deeper on 2010-024415-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024415-14.